Year All20242023202220212020201920182017 Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency Jul 02, 2024 Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH) Jun 21, 2024 Inozyme Pharma to Present at the Jefferies Global Healthcare Conference May 30, 2024 Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences May 23, 2024 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference May 08, 2024 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights May 07, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency Apr 08, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 05, 2024 Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference Apr 02, 2024
Year All20242023202220212020201920182017 Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency Jul 02, 2024 Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH) Jun 21, 2024 Inozyme Pharma to Present at the Jefferies Global Healthcare Conference May 30, 2024 Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences May 23, 2024 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference May 08, 2024 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights May 07, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency Apr 08, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 05, 2024 Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference Apr 02, 2024
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH) Jun 21, 2024
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences May 23, 2024
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference May 08, 2024
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights May 07, 2024
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency Apr 08, 2024